News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

27

March

2024

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
Read More
13

March

2024

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
Read More
13

March

2024

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
Read More
27

February

2024

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
Read More
23

February

2024

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100
Read More
20

February

2024

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classical Psychedelic-Based Compounds
Read More
5

February

2024

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
Read More
1

February

2024

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
Read More
16

January

2024

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
Read More
10

January

2024

Clearmind Medicine Completed Type A Meeting with the FDA
Read More
14

December

2023

Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
Read More
28

November

2023

Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program
Read More
27

November

2023

Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
Read More
21

November

2023

Clearmind Medicine Announces 1-for-30 Reverse Share Split
Read More
17

November

2023

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
Read More